Central Serous Chorioretinopathy
Conditions
Brief summary
Patients with central serous chorioretinopathy (CSC) will be monitored with laser speckle flow graphy (LSFG), swept source optical coherence tomography (SS-OCT) and SS-OCT angiography (SS-OCTA). The aim is to unveil the flow and pulse wave characteristics of the choroidal circulation in acute CSC and chronic CSC.
Detailed description
Acute CSC - The proposed study tests the hypothesis that choroidal blood flow characteristics are related to the eventual resolution of subretinal fluid. Such relation can shed light on pathophysiological disease mechanisms and constitute a biomarker for disease activity. Chronic CSC - The proposed study tests the hypothesis that choroidal blood flow characteristics will change in response to standard treatment with PDT. The research of such changes will increase the understanding of the treatment response. This knowledge will help in the effort to understand the why some patients are non-responsive to the treatment.
Interventions
DRUGVerteporfin
Chronic CSC are receiving one treatment before the observation period.
Sponsors
Helse Stavanger HF
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
- * Able to sign informed consent * Possible to obtain fundus imaging * Acute CSC ˂4 months of duration in one eye, defined as: 1. Subfoveal presence of SRF on OCT 2. Present attack is 1st -3rd attack of CSC b) Patient history and examination consistent with acute CSC c) Characteristic appearance of acute CSC on fundus autofluorescence (FAF) and OCT * Chronic CSC ≥4 months of duration in one eye, defined as: 1. Subfoveal presence of SRF on OCT 2. Subjective visual loss/symptoms 3. Characteristic appearance of chronic CSC on FAF, fluorescein angiography (FA), and indocyanin angiography (ICGA) and OCT 4. Patient history and examination consistent with chronic CSC
Exclusion criteria
* History of retinal disease other than CSC (e.g. retinal detachment) * Contraindications for FA, ICGA or PDT (only for chronic CSC)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in mean blur rate | 6 months | Relative changes in choroidal blood flow |
| Change in pulse wave form analysis | 6 months | Changes in the shapes of pulse curves |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in choroidal density | 6 months | Changes in the tissue density |
| Change in choroidal thickness | 6 months | Changes in the morphology of the choroid |
Countries
Norway
Contacts
Primary ContactVegard Forsaa, MD PhD
Outcome results
None listed